INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (formerly INVO Fertility, Inc.) on March 8, 2021, covering events occurring on March 2, 2021. The filing details a material amendment to the company's existing Distribution Agreement with Ferring International Center S.A. ("Ferring").
Key Financial Metrics and Agreements
- Immediate Revenue Impact: Ferring agreed to purchase 2,004 units of Product (334 units of 6) for $501,000 in March 2021.
- Minimum Annual Target Satisfaction: The $501,000 purchase satisfies the Minimum Annual Target for Calendar Year 2020 in full.
- Contingent Payment: Ferring agreed to pay a one-time, non-refundable fee of $3,000,000 upon FDA approval of a Product Label Enhancement, provided this occurs at least three years prior to the agreement's expiration.
- Operational Expansion: INVO is permitted to establish up to seven (7) "INVO Clinics" to commercialize the Product, subject to specific oversight and consent requirements.
- Product Repurchase Terms: For INVO Clinics, INVO may repurchase Product from Ferring at a price of $100 plus the then-current purchase price per unit, capped at 10% of Ferring's current inventory per 90-day period.
Material Changes Versus Prior Period
The filing represents a significant modification to the November 12, 2018 Distribution Agreement. Key changes include:
- Introduction of a mechanism for INVO to operate its own clinics (INVO Clinics) to commercialize the Product, which was previously restricted under the exclusive license.
- Establishment of a new $3 million milestone payment tied to regulatory label enhancements.
- Clarification that revenue generated from INVO Clinics counts toward Ferring's Minimum Annual Targets.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on March 8, 2021, stating that the amendment expands the clinic opportunity and addressable market under the U.S. Commercialization Agreement.
Risks and Contingencies:
- Regulatory Dependency: The $3 million payment is contingent on FDA approval of a Product Label Enhancement within a specific timeframe.
- Operational Constraints: Establishment of INVO Clinics requires 90 days' advance notice and Ferring's consent for any clinic beyond the initial seven. Clinics must be under the oversight of a reproductive endocrinologist.
- Exclusivity Obligations: INVO covenants to exclusively require and promote the use of Ferring's pharmaceutical product Menopur and other Ferring Fertility Products in connection with INVO Cycles.
Investor Verification Checklist
- Verify the status of the FDA Product Label Enhancement application to assess the likelihood of the $3 million contingent payment.
- Confirm the timeline and regulatory approvals required to establish the first INVO Clinic.
- Review the full text of Amendment No. 1 (Exhibit 10.1) for detailed definitions of "Product," "Territory," and "Term."
- Assess the impact of the $100 premium on repurchased Product on the gross margins of the new INVO Clinics.
- Monitor future filings for updates on the satisfaction of Minimum Annual Targets for 2021 and beyond.